Pathways for aberrant angiogenesis in pancreatic cancer - sprookjes - yvandenbroek - TriplyDB

Pathways for aberrant angiogenesis in pancreatic cancer

Pathways for aberrant angiogenesis in pancreatic cancer

http://www.wikidata.org/entity/Q24800215

about

Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells Critical role of NF-κB in pancreatic cancer Evolution and applications of plant pathway resources and databases Challenges of Pancreatic Cancer.Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 Imaging in pancreatic disease.Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases.Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis Evolution of systemic therapy for advanced pancreatic cancer.Phenotype and genotype of pancreatic cancer cell lines Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat.RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.ZIP4 upregulates the expression of neuropilin-1, vascular endothelial growth factor, and matrix metalloproteases in pancreatic cancer cell lines and xenografts Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.Harnessing preclinical mouse models to inform human clinical cancer trials.A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer.Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review CASTIN: a system for comprehensive analysis of cancer-stromal interactome.Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro.Antiangiogenic therapy in human gastrointestinal malignancies.What is recent in pancreatic cancer immunotherapy?Molecular mechanisms of pancreatic cancer and potential targets of treatment.Medical treatment of pancreatic cancer.Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Gemcitabine in the treatment of metastatic pancreatic cancer.Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue

P2860

Q26766065-15A86473-D2B5-40F9-BA0C-EF13E41BDAC9 Q26864198-53B8BA7F-EDA1-47D3-9F09-9E3D95F3EE59 Q26865772-56721C2A-1A05-46FA-9BA6-D5A4F7FC444E Q28080671-80CCE2EF-223C-40DB-9098-C89DCC1468AA Q28115209-A8A34F27-50DD-47BF-A21F-915F70D5A629 Q28943270-49642204-1DC2-449F-A0FE-975271766F78 Q30275458-CB10B814-1BB5-4B4F-81A2-20280828AE32 Q30317589-294192F2-E7DF-4A9D-B152-79401EAFD2FE Q30416185-0553B49E-EA45-4B32-8251-47A7D27D1B79 Q30908891-D771F48A-4CE1-4132-8D56-CDEB91B4F553 Q33557413-53975594-7767-49DD-87D2-ABD0BA349272 Q33814471-9167B559-CC94-483A-A283-77C164D4C926 Q33894658-A65433DC-9917-4BA5-ABDB-2991C4C5338C Q33946423-28983960-F32A-48FA-9DF9-C7AF9579AFEC Q33951007-5EED103E-BA81-4A5D-9D64-37F7E4915DFA Q33959544-5044B0B6-031D-41F6-8A3A-FAB9E03B6D74 Q34049260-D48EA62D-CF3F-4136-833E-8367CCD8B5E1 Q34313870-206356C1-14C3-41BB-9BDE-BA9FFDA32946 Q34316618-29D0BDD2-38DB-42DD-A342-F1C1E1285635 Q34371518-38C8D6BB-111E-41CC-8D3E-D1CC5D1DAA37 Q34498952-736ECD61-28A7-49C3-B253-E51A2696DD9F Q35194888-00F824B5-C93A-4BF4-BA08-F0F1BA4BF509 Q35212896-CBDD041B-C5F2-49C3-8335-EE78AF989BE2 Q35608989-CBA84AB2-EE59-4116-9266-3D667AB9CF82 Q35683181-289D776E-C759-4818-A7CF-6243B00227A3 Q35855631-8C882F9B-E6E3-40F4-91F1-BDAD1DDDDFD3 Q35886496-23678149-F3B7-493E-A3C7-5469375073ED Q35904219-2123650B-64BD-461E-AC20-349C1A229B5A Q36061770-05311E7D-AAEC-41E5-B0F0-D1DE030ADB62 Q36187726-4DD5273F-907F-43C1-925E-370687FC70EE Q36227239-EB83EE8D-9343-43E3-BB25-727B89B00A7B Q36496250-DEF4029E-40D3-424E-9415-B4E0F7E0B5FF Q36591067-116D4DDF-F6BE-4B12-91FC-9C85D3210F89 Q36665335-87F7302F-0617-4FF4-8819-6B40B9567524 Q36758436-E4910CB9-58E1-45DA-9B26-C66F1BCD648E Q36788494-3677D4DB-6514-43CB-9EA7-7659FB8F5733 Q37093547-C59EB1F9-7056-4CBE-95DB-03077E69729C Q37134412-43CF3910-F742-4BFD-9D0E-3EE5BB1D9868 Q37341673-0CB22988-94DE-4819-B8B5-47332F6AA6B0 Q37629083-5FFCE72F-1136-4017-8769-E03B7AF09BBC

P2860

Pathways for aberrant angiogenesis in pancreatic cancer

http://www.wikidata.org/entity/Q24800215

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Pathways for aberrant angiogenesis in pancreatic cancer

@ast

Pathways for aberrant angiogenesis in pancreatic cancer

@en

Pathways for aberrant angiogenesis in pancreatic cancer

@nl

type

label

Pathways for aberrant angiogenesis in pancreatic cancer

@ast

Pathways for aberrant angiogenesis in pancreatic cancer

@en

Pathways for aberrant angiogenesis in pancreatic cancer

@nl

prefLabel

Pathways for aberrant angiogenesis in pancreatic cancer

@ast

Pathways for aberrant angiogenesis in pancreatic cancer

@en

Pathways for aberrant angiogenesis in pancreatic cancer

@nl

P1433

Q24800215-95BBB500-CED7-4BC2-AB06-4BE60EEA05D3

P1476

Q24800215-A8AF9C1D-73C2-4618-A9E3-3CF1F45A820E

P2093

Q24800215-A4541934-6D42-4BD6-B71C-4AE5E524321A

P2860

Q24800215-003B1773-D82D-4826-B963-EF52450F7DA5

Q24800215-03D802DE-FB15-481A-91CB-1C1E7624A001

Q24800215-057F809B-A724-4B37-B9E0-B85956B43B7A

Q24800215-06D894BC-F40F-4415-B5A5-E50EEF2C249E

Q24800215-0740ECF5-41E3-47C8-8228-F73B08F77C7F

Q24800215-0773390F-5ABB-4922-A0D0-7BD88394056C

Q24800215-087C1A43-EB24-42F8-95BF-FB96B38E989C

Q24800215-0910822A-06D9-48A4-870A-E0E900A72204

Q24800215-09308747-98A6-4291-A28F-9618A292064E

Q24800215-0C441841-2CB5-46E6-AD81-9B220C108FC6

P2888

Q24800215-5567D21C-4727-4F26-886E-C70DD021C4E3

P304

Q24800215-144195A0-FEDB-4334-845C-04F37B26FB06

P31

Q24800215-A6A3B7E4-4966-4F18-9CDB-4697F16C2894

Q24800215-BF628DDE-DA3D-4559-AAB0-7EB2BD31D67E

P3181

Q24800215-73B20D53-29A4-4C2C-8430-88BFB340EFDD

P356

Q24800215-A35F3DF1-5A22-4AF9-99EB-F1C3D1FC7753

P407

Q24800215-42B51F0A-D571-42FC-AC51-27F4D93D01BC

P433

Q24800215-53580860-4B61-4227-ADA4-E2100D856E7F

P478

Q24800215-83CB950A-5E1E-4AE8-BEA9-61D3F807833B

P577

Q24800215-1D0BF19A-DAE5-4EF0-9E8B-757B0E01DB39

P5875

Q24800215-0260C617-CA2C-4B6E-86AC-BB496B9495D3

P6179

Q24800215-922F9CB7-4410-44DC-A067-FDFBDD5694B6

P698

Q24800215-D96D4719-9A9E-411C-846E-D35E4C708875

P921

Q24800215-85AC0CA0-3F3D-410E-9A6E-9885FC19DC32

P932

Q24800215-C5B78307-B8F8-43DD-896E-4CCE9195663C

P3181

P356

P1433

Molecular Cancer

P1476

Pathways for aberrant angiogenesis in pancreatic cancer

@en

P2093

M Korc

http://www.w3.org/2001/XMLSchema#string

P2860

TGF-beta signal transduction

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Latent transforming growth factor-beta: structural features and mechanisms of activation

Molecular cloning of a novel vascular endothelial growth factor, VEGF-D

P2888

P304

8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2611048

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1476-4598-2-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8427193

http://www.w3.org/2001/XMLSchema#string

P6179

1049032930

http://www.w3.org/2001/XMLSchema#string

P698

12556241

http://www.w3.org/2001/XMLSchema#string

P921

pancreatic cancer

P932

149422

http://www.w3.org/2001/XMLSchema#string